RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 5, 2014, Pages 2729-2736

  Li, Xin Xiang ^a,b   Zheng, Hong Tu ^a,b   Peng, Jun Jie ^a,b   Huang, Li Yong ^a,b   Shi, De Bing ^a,b   Liang, Lei ^a,b   Cai, San Jun ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

CITED2; Colorectal cancer; CTNNAL1; FZD7; Irinotecan; RNA seq

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; RNA; TUMOR MARKER;

ANALOGS AND DERIVATIVES; BIOLOGY; CACO 2 CELL LINE; COLORECTAL NEOPLASMS; DOSE RESPONSE; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; IC50; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SEQUENCE ANALYSIS;

CACO-2 CELLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COMPUTATIONAL BIOLOGY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HCT116 CELLS; HT29 CELLS; HUMANS; INDIVIDUALIZED MEDICINE; INHIBITORY CONCENTRATION 50; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RNA, NEOPLASM; SEQUENCE ANALYSIS, RNA; TOPOISOMERASE I INHIBITORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902476265     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR and Buchler MW. Colorectal cancer. Lancet 2005; 365: 153-165.
2. Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P and Ryan A. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2008; 12: iii-ix, xi-162.
3. Popowich DA and Halverson AL. Medical oncology: Multimodality therapy in unresectable colorectal cancer. Nat Rev Clin Oncol 2009; 6: 305-306.
4. Yim KL and Cunningham D. Chemotherapy: Optimizing irinotecan regimens for colorectal cancer. Nat Rev Clin Oncol 2009; 6: 560-561.
5. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S and Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19: 1501-1518.
6. Cunningham D, Maroun J, Vanhoefer U and Van Cutsem E. Optimizing the use of irinotecan in colorectal cancer. Oncologist 2001; 6: 17-23.
7. Ikeguchi M, Arai Y, Maeta Y, Ashida K, Katano K and Wakatsuki T. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer. Surg Today 2011; 41: 1196-1199.
8. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
9. Shen J, Wei J, Wang H, Yue G, Yu L, Yang Y, Xie L, Zou Z, Qian X, Ding Y, Guan W and Liu B. A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer. J Transl Med 2013; 11: 73.
10. Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ, Hernandez-Losa J, Mazzolini R, Rodrigues P, Bazzocco S, Carreras MJ, Espin E, Armengol M, Wilson AJ, Mariadason JM, Ramon YCS, Tabernero J, Schwartz S Jr. and Arango D. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Clin Cancer Res 2010; 16: 2375-2382.
11. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MK and Seymour MT. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008; 26: 2690-2698.
12. Desai SD, Wood LM, Tsai YC, Hsieh TS, Marks JR, Scott GL, Giovanella BC and Liu LF. ISG15 as a novel tumor biomarker for drug sensitivity. Mol Cancer Ther 2008; 7: 1430-1439.
13. Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E and Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24: 4069-4077.
14. Bandyopadhyay K and Gjerset RA. Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines. Biochemistry 2011; 50: 704-714.
15. Bandyopadhyay K, Li P and Gjerset RA. CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity. PLoS One 2012; 7: e50427.
16. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ and Pachter L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010; 28: 511-515.
17. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R and Garraway LA. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
18. Chou YT, Hsieh CH, Chiou SH, Hsu CF, Kao YR, Lee CC, Chung CH, Wang YH, Hsu HS, Pang ST, Shieh YS and Wu CW. CITED2 functions as a molecular switch of cytokine-induced proliferation and quiescence. Cell Death Differ 2012; 19: 2015-2028.
19. Wu ZZ, Sun NK and Chao CC. Knockdown of CITED2 using short-hairpin RNA sensitizes cancer cells to cisplatin through stabilization of p53 and enhancement of p53-dependent apoptosis. J Cell Physiol 2011; 226: 2415-2428.
20. Wu ZZ, Lu HP and Chao CC. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells. Biochem Pharmacol 2010; 80: 262-276.
21. van Agthoven T, Sieuwerts AM, Veldscholte J, Meijer-van Gelder ME, Smid M, Brinkman A, den Dekker AT, Leroy IM, van Ijcken WF, Sleijfer S, Foekens JA and Dorssers LC. CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. Br J Cancer 2009; 101: 1824-1832.
22. Bai L and Merchant JL. A role for CITED2, a CBP/p300 interacting protein, in colon cancer cell invasion. FEBS Lett 2007; 581: 5904-5910.
23. Lou X, Sun S, Chen W, Zhou Y, Huang Y, Liu X, Shan Y and Wang C. Negative feedback regulation of NF-kappaB action by CITED2 in the nucleus. J Immunol 2011; 186: 539-548.
24. Lau WM, Doucet M, Huang D, Weber KL and Kominsky SL. CITED2 modulates estrogen receptor transcriptional activity in breast cancer cells. Biochem Biophys Res Commun 2013; 437: 261-266.
25. Li Q, Ramirez-Bergeron DL, Dunwoodie SL and Yang YC. Cited2 gene controls pluripotency and cardiomyocyte differentiation of murine embryonic stem cells through Oct4 gene. J Biol Chem 2012; 287: 29088-29100.
26. Bakker WJ, Harris IS and Mak TW. FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. Mol Cell 2007; 28: 941-953.
27. Agrawal A, Gajghate S, Smith H, Anderson DG, Albert TJ, Shapiro IM and Risbud MV. Cited2 modulates hypoxia-inducible factor-dependent expression of vascular endothelial growth factor in nucleus pulposus cells of the rat intervertebral disc. Arthritis Rheum 2008; 58: 3798-3808.
28. Kreiseder B, Orel L, Bujnow C, Buschek S, Pflueger M, Schuett W, Hundsberger H, de Martin R and Wiesner C. alpha-Catulin downregulates E-cadherin and promotes melanoma progression and invasion. Int J Cancer 2013; 132: 521-530.
29. Liang CH, Chiu SY, Hsu IL, Wu YY, Tsai YT, Ke JY, Pan SH, Hsu YC, Li KC, Yang PC, Chen YL and Hong TM. alpha-Catulin drives metastasis by activating ILK and driving an alphavbeta3 integrin signaling axis. Cancer Res 2013; 73: 428-438.
30. Cao C, Chen Y, Masood R, Sinha UK and Kobielak A. alpha-Catulin marks the invasion front of squamous cell carcinoma and is important for tumor cell metastasis. Mol Cancer Res 2012; 10: 892-903.
31. Wiesner C, Winsauer G, Resch U, Hoeth M, Schmid JA, van Hengel J, van Roy F, Binder BR and de Martin R. Alpha-catulin, a Rho signalling component, can regulate NF-kappaB through binding to IKK-beta, and confers resistance to apoptosis. Oncogene 2008; 27: 2159-2169.
32. Fan LC, Chiang WF, Liang CH, Tsai YT, Wong TY, Chen KC, Hong TM and Chen YL. alpha-Catulin knockdown induces senescence in cancer cells. Oncogene 2011; 30: 2610-2621.
33. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, Deng X, Chen L, Kim CC, Lau S, Somlo G and Yen Y. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 2011; 30: 4437-4446.
34. Ueno K, Hazama S, Mitomori S, Nishioka M, Suehiro Y, Hirata H, Oka M, Imai K, Dahiya R and Hinoda Y. Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells. Br J Cancer 2009; 101: 1374-1381.
35. Ueno K, Hiura M, Suehiro Y, Hazama S, Hirata H, Oka M, Imai K, Dahiya R and Hinoda Y. Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia 2008; 10: 697-705.